It comprises an adenine base editor-expressing messenger RNA and an optimised RNA targeting PCSK9. The drug is currently tested in the Heart-2 open-label Phase 1b clinical trial in two patient populations: adults with heterozygous familial hypercholesterolaemia (HeFH) and adults with premature coronary artery disease (CAD). This evidence concerns the gene PCSK9 and coronary artery disorder.